Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia

被引:49
|
作者
Shaarawy, M
ElDidy, H
机构
[1] Dept. of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo
关键词
fibronectin; plasminogen activator inhibitor type 1; thrombomodulin; preeclampsia; eclampsia;
D O I
10.1016/S0020-7292(96)02755-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Preeclampsia has been recently suggested to be an endothelial cell disorder. This study was initiated to determine the levels of various biomarkers of endothelial damage in preeclampsia and eclampsia. Methods: Blood samples were withdrawn from 70 pregnant women in their third trimester grouped as 25 mild preeclampsia, 15 severe preeclampsia, 10 eclampsia and 20 normotensive healthy women (controls) for the determination of thrombomodulin by ELISA, PAI-1 by urokinase method and fibronectin by radial immunodiffusion. Results were statistically analyzed by Student's t-test. Results: Circulation levels of PAI-1, thrombomodulin and fibronectin were increased with increasing severity of the disease. Thrombomodulin was the only parameter which did not change significantly in mild preeclampsia. The average percent increments in preeclampsia and eclampsia were 63%, 102% and 132%, respectively. Conclusions: These results demonstrate that fibronectin may be a more valuable biomarker than thrombomodulin and PAI-I for the assessment of endothelial damage in preeclampsia and eclampsia.
引用
收藏
页码:135 / 139
页数:5
相关论文
共 50 条
  • [21] Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study
    Bosnyak, Z
    Forrest, KYZ
    Maser, RE
    Becker, D
    Orchard, TJ
    DIABETIC MEDICINE, 2003, 20 (02) : 147 - 151
  • [22] PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN PLASMA AND PLATELETS
    BOOTH, NA
    MACGREGOR, IR
    BENNETT, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 68 (04) : 509 - 509
  • [23] PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN PLASMA AND PLATELETS
    BOOTH, NA
    SIMPSON, AJ
    CROLL, A
    BENNETT, B
    MACGREGOR, IR
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (03) : 327 - 333
  • [24] Plasminogen activator inhibitor (PAI-1) as a cardiovascular risk factor
    Ilic, M
    Majkic-Singh, N
    Lalic, K
    JUGOSLOVENSKA MEDICINSKA BIOHEMIJA-YUGOSLAV MEDICAL BIOCHEMISTRY, 1998, 17 (03): : 194 - 194
  • [25] Theaflavin digallate inactivates plasminogen activator inhibitor (PAI-1)
    Jankun, J. J.
    Skrzypczak-Jankun, E. S. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 : 54 - 55
  • [26] INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) WITH VITRONECTIN
    SALONEN, EM
    VAHERI, A
    POLLANEN, J
    STEPHENS, R
    ANDREASEN, P
    MAYER, M
    DANO, K
    GAILIT, J
    RUOSLAHTI, E
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1989, 264 (11) : 6339 - 6343
  • [27] DISTRIBUTION OF PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN TISSUES
    SIMPSON, AJ
    BOOTH, NA
    MOORE, NR
    BENNETT, B
    JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (02) : 139 - 143
  • [28] Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): Mapping the binding sites on PAI-1 and Vn
    Schroeck, F
    de Prada, NA
    Sperl, S
    Schmitt, M
    Magdolen, V
    BIOLOGICAL CHEMISTRY, 2002, 383 (7-8) : 1143 - 1149
  • [29] ANALYSIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 (PAI-1) BY LIGHT SPECTROSCOPY
    STRANDBERG, L
    ALESHKOV, S
    MING, F
    JOHANSSON, L
    KAROLIN, J
    NY, T
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1329 - 1329
  • [30] FUNCTIONAL INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 (PAI-1) AND HEPARIN
    EHRLICH, HJ
    KEIJER, J
    PREISSNER, KT
    GEBBINK, RK
    PANNEKOEK, H
    BIOCHEMISTRY, 1991, 30 (04) : 1021 - 1028